Rituximab
Brand Names: Rituxan
Methodology & AI Transparency ⓘ
Rituximab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage rituxan: is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ).
- 2 Real-world patient consensus: 83% patient "Worth It" rating across 16 anonymous logs for Rituximab (RxNorm 1657862).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $114.61 cash mean against $280.79 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Rituximab include nausea (8.5%), headache (8.2%), dizziness (6.7%).
Ask our AI Specialists anything about Rituximab
Rituximab Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage rituxan: is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
12.1 Mechanism of Action Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis.
With Approximately 3–14 hours terminal plasma half-life for Rituximab residence kinetics and Complete (~100%) parenteral systemic delivery for Rituximab (10 mg/mL Injection, Solution) bioavailability, Rituximab undergoes phase i/ii hepatic conjugation of rituximab coupled with glomerular and tubular renal excretion and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after rituximab administration.
Standard adult regimens span 10 mg/mL Injection, Solution, Organ-function-adjusted Rituximab maintenance interval. Prescribers screen specifically against known hypersensitivity to rituximab or structurally related cd20-directed cytolytic antibody compounds; concomitant contra-labeled cyp/transporter therapies during active rituximab administration, while community micro-logs most frequently note nausea (8.5% of reports), headache (8.2% of reports), dizziness (6.7% of reports).
Avoid overlapping cd20-directed cytolytic antibody prescriptions alongside Rituximab to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Rituximab maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Rituximab or structurally related cd20-directed cytolytic antibody compounds
- Concomitant contra-labeled CYP/transporter therapies during active Rituximab administration
Logged Side-Effect Incidence (16 Reports)
Rituximab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rituximab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden: What a 258-Participant Study Found These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 single-drug treatment for previously untreated LTBFL. Clinical lymphoma, myeloma & leukemia • 2022-02-15 • Phase III Randomized Trial | N = 258 | 93/100 | PMID 34686445 ↗ |
| Can This Approach Help? Inside the Latest Research on Rituximab plus leflunomide in autoimmune joint pain (rheumatoid arthritis): a The primary endpoint was not reached, but rituximab + LEF demonstrated clinical benefits vs LEF in secondary endpoints. Rheumatology (Oxford, England) • 2021-11-03 • Phase III Randomized Trial | N = 93 | 88/100 | PMID 33738492 ↗ |
| Can This Approach Help? Inside the Latest Research on Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the Disease activity and treatment burden, including hospitalization and rescue treatments, remained low, indicating a potential benefit of rituximab on the long-term disease trajectory. European journal of neurology • 2025-11-15 • Phase III Randomized Trial | N = 47 | 88/100 | PMID 41194516 ↗ |
| Can This Approach Help? Inside the Latest Research on Six-year follow-up of participants in two clinical trials of rituximab or After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way. PloS one • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39042627 ↗ |
| Can This Approach Help? Inside the Latest Research on Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Improved long-term efficacy with R 2 versus R-placebo and manageable safety with R 2 were observed in patients with FL, including those 70 years and older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-06-15 • Phase III Randomized Trial | N = 66 | 88/100 | PMID 41990300 ↗ |
Rituximab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.6200/unit (~$78.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $280.79 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $114.61 / mo | View logs ↓ |
Rituximab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rituximab RxNorm Concept ID | 1657862 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.6200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $280.79 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $114.61 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Rituximab Patient Community, Cohort Filters & Dosage Logs
Deterministic Rituximab reference combining NIH RxNorm (1657862), Medicaid NADAC ($2.6200/unit), and anonymous cohort outcomes (83% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Rituximab community threads and patient logs by age, biological sex, dosage, and treatment duration.